CTM

Center For Translational and Molecular medicine

Actuality

About us

The Research Centre UMR1231- LNC was initially created as UMR866 “Lipids, Nutrition, Cancer-LNC” on 1 January 2007 and is the result of a joint programme of several groups which led to the signature of a four-year contract with INSERM, the University of Burgundy and the EPHE. The founding teams of the LNC Research Centre are from INSERM units U498 (“Intravascular metabolism of lipoproteins”), U517 (“Cell death and cancer”), and EPI-106 (“Epidemiology of digestive cancers”)

Publications

Francois Hermetetjanvier 25, 2024Privat M, Massot A, Hermetet F, Al Sabea H, Racoeur C, Mabrouk N, Cordonnier M, Moreau M, Collin B, Bettaieb A, Denat F, Bodio E, Bellaye PS, Goze C, Paul C. Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models. J Med Chem. 2024 Jan 25. doi: 10.1021/acs.jmedchem.3c02120. Epub ahead of print. PMID: 38270503. Avec la participation de la Plateforme CRISPR Genomics (CRIGEN) de l’UMS58 BIOSAND à Dijon. Conseil, conception et réalisation à façon d’expériences d’édition génomique et de criblages génétiques par CRISPR-Cas9. Avec la participation des Plateformes d’Imagerie et de radiothérapie précliniques (PIRP) et d’Imagerie et de Cytométrie (Imaflow) de l’UMS58 BIOSAND à Dijon. https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.3c02120 [...] Lire la suite…
Francois Hermetetnovembre 9, 2023Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. BMC Cancer. 2023 Nov 9;23(1):1080. doi: 10.1186/s12885-023-11534-6. PMID: 37946136; PMCID: PMC10633948 Trial registration: This study is registered on ClinicalTrials.gov: NCT05259319, since February 28th, 2022. [...] Lire la suite…
Francois Hermetetaoût 10, 2023Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nat Med. 2023 Aug;29(8):2087-2098. doi: 10.1038/s41591-023-02497-z. Epub 2023 Aug 10. PMID: 37563240; PMCID: PMC10427431. https://pubmed.ncbi.nlm.nih.gov/37563240/ [...] Lire la suite…